Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559359 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis and Eczema, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT05559359 is a Phase 3 study of Atopic Dermatitis and Eczema that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 367 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05559359, a Phase 3 study of Atopic Dermatitis and Eczema, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG Topical Corticosteroid (TCS)
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Antelope Valley Clinical Trials - Lancaster
- Dermatology Research Associates - Los Angeles
- Integrative Skin Science and Research - Sacramento
- Rady's Children Hospital San Diego - Dermatology - San Diego
Florida
- Solutions Through Advanced Research - Jacksonville
- ForCare Clinical Research - Tampa
Alabama
- Clinical Research Center of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Research Trials - North Little Rock
Connecticut
- UConn Health - Farmington
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05559359
The ClinicalTrials.gov registry entry for NCT05559359 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (40% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05559359 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05559359 about?
NCT05559359 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis". The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT05559359?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2022-10-18. Estimated completion is 2026-12.
What conditions does trial NCT05559359 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT05559359?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), Topical Corticosteroid (TCS) (DRUG).
Who is sponsoring clinical trial NCT05559359?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559359 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.